Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNSTNASDAQ:MRSNNASDAQ:RYTMNASDAQ:TRILNASDAQ:ZGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AMRSNMersana Therapeutics$0.29+3.7%$0.36$0.26▼$2.83$36.14M0.792.71 million shs1.86 million shsRYTMRhythm Pharmaceuticals$65.78-1.7%$62.82$40.46▼$69.89$4.18B2.26557,108 shs628,374 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics+3.68%-10.77%-16.86%-4.26%-84.24%RYTMRhythm Pharmaceuticals-1.71%+7.06%+0.16%+40.10%+61.17%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMRSNMersana Therapeutics3.5235 of 5 stars3.51.00.04.10.62.50.0RYTMRhythm Pharmaceuticals3.807 of 5 stars3.52.00.04.31.30.80.6TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation Pharmaceuticals 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$5.201,693.10% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$77.3117.53% UpsideTRILTrillium Therapeutics 0.00N/AN/AN/AZGNXZogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CNST, ZGNX, MRSN, RYTM, and TRIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.006/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/8/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/8/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $92.004/8/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $80.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AMRSNMersana Therapeutics$40.50M0.89N/AN/A($0.08) per share-3.63RYTMRhythm Pharmaceuticals$130.13M32.16N/AN/A$0.35 per share187.93TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AMRSNMersana Therapeutics-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest CNST, ZGNX, MRSN, RYTM, and TRIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39MRSNMersana TherapeuticsN/A1.831.83RYTMRhythm PharmaceuticalsN/A3.303.13TRILTrillium TherapeuticsN/A19.8219.82ZGNXZogenix0.883.634.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/AMRSNMersana Therapeutics93.92%RYTMRhythm PharmaceuticalsN/ATRILTrillium Therapeutics87.15%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%MRSNMersana Therapeutics13.00%RYTMRhythm Pharmaceuticals6.10%TRILTrillium Therapeutics9.10%ZGNXZogenix4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableMRSNMersana Therapeutics150124.63 million108.43 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableZGNXZogenix21856.23 million53.92 millionOptionableCNST, ZGNX, MRSN, RYTM, and TRIL HeadlinesRecent News About These CompaniesAfter epilepsy setback, Zogenix buys Modis and rare disease drug for $400mJanuary 2, 2025 | pharmaphorum.comPNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMOrally Inhaled DihydroergotamineFebruary 13, 2024 | medscape.comMMRI in HeadacheAugust 25, 2023 | medscape.comMKratom: What We KnowAugust 13, 2023 | medscape.comMAlcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalMay 10, 2023 | news.google.comNGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRMay 4, 2023 | news.google.comNNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsApril 28, 2023 | news.google.comNThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheApril 25, 2023 | medscape.comMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsApril 24, 2023 | news.google.comNAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalApril 24, 2023 | news.google.comNDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalApril 19, 2023 | news.google.comNForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comApril 19, 2023 | news.google.comNDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome NewsApril 18, 2023 | news.google.comNUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalApril 17, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNST, ZGNX, MRSN, RYTM, and TRIL Company DescriptionsConstellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Mersana Therapeutics NASDAQ:MRSN$0.29 +0.01 (+3.68%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$0.30 +0.01 (+1.72%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Rhythm Pharmaceuticals NASDAQ:RYTM$65.78 -1.15 (-1.71%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$65.74 -0.04 (-0.06%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Trillium Therapeutics NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Zogenix NASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
